The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1191
September 13, 2004
View Complete Issue         Table of Contents 2019 
Rifaximin (Xifaxan) for Travelers' Diarrhea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rifaximin (Xifaxan) for Travelers' Diarrhea
September 13, 2004 (Issue: 1191)
Rifaximin (Xifaxan - Salix), a non-absorbed oral antibiotic derived from rifampin (Rifadin, and others), has been approved by the FDA for treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years of age...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rifaximin (Xifaxan) for Travelers' Diarrhea
Article code: 1191b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.